Theracion's Future
2023
2023
- "ActiClot", clinical trial completed.
- Drug contained absorbable hemostat for human in GI field, “EndoStat active” launched.
- Upgraded absorbable hemostat for human, "Hemogram" launched.
Since 2022,
2022
- Drug contained absorbable hemostat for human, "ActiClot" lauched.
- Absorbable hemostat for human in GI field, "EndoStat" launched.
- "OOZFIX", clinical trial completed.
In 2021,
2021
- CE certificates acuired "Tableau Wax"
- "Tableau Wax", clinical trial completed.
In 2020,
2020
- Acquired venture business certification
- Absorbable topical hemostat for human, "OOZFIX" launched.
- Absorbable topical hemostat for animal, "VetiStat" launched.
- Topical hemostatic dressing for animal, "VetiClot" launched.
In 2019,
2019
- Quality certificates acquired ISO13485
- Acquired GMP certification
- Absorbable bone hemostat for human, "Tableau Wax" launched.
- Adhesive wound dressing for animal, "Vetiderm-Q" launched.
- Acquired TIPS (Tech Incubator Program for Startup) program
In 2018
2018
- Quality certificates acquired ISO9001
- Absorbable bone hemostat for animal, "Veti-Wax" launched.
In 2017
2017
- R&D center was founded.
- Acquired medical device manufacturing qualification
- Topical hemostat for animal, "AniClot" series launched.
In 2016
2016
- Theracion Biomedical was founded.
- Factory registration
- Conduct four national research projects